BBIN - ETF AI Analysis
Top Page
JPMorgan BetaBuilders International Equity ETF (BBIN)
BBIN vs. SPDR S&P 500 ETF (SPY)
- AUM
- 6.55B
- Region
- Developed Markets
- Expense Ratio
- 0.07%
- Beta
- 0.72
- Issuer
- JPMorgan
- Inception Date
- Dec 03, 2019
- Dividend Yield
- 3.75%
- Asset Class
- Equity
- Index Tracked
- Morningstar Developed Markets ex-North America Target Market Exposure Index
BBIN Summary
BBIN is the JPMorgan BetaBuilders International Equity ETF, which follows the Morningstar Developed Markets ex-North America Index. It gives you broad exposure to large and mid-sized companies outside the U.S., across countries like Japan, the UK, Germany, and Australia. The fund holds well-known names such as Nestlé and Shell, along with banks, industrial firms, and healthcare companies, making it a simple way to diversify beyond the U.S. market and tap into global growth. A key risk is that international stocks can go up and down with global markets and currency swings.
How much will it cost me?
BBIN has an annual expense ratio of 0.07%, which means you’ll pay about $0.70 per year for every $1,000 invested. This cost is lower than the average ETF because BBIN is a passively managed fund that tracks an index rather than paying managers to pick individual stocks.
What would affect this ETF?
BBIN could benefit if developed markets outside North America grow steadily, especially in sectors like financials, health care, and technology, and if global trade remains strong, supporting major holdings such as ASML, Nestlé, and HSBC. On the downside, slower economic growth in Europe or Japan, rising interest rates that pressure banks, or stricter regulations on energy, pharmaceuticals, or tech companies could weigh on the ETF’s performance.
BBIN Top 10 Holdings
BBIN’s story is driven by a handful of heavyweight international names. ASML has been a key engine for the fund, with strong year-to-date gains even after some recent wobbling, while SAP has turned more upbeat lately, adding a tech tilt from Europe. Health care giants Roche and Novartis are steadily pulling their weight, giving the portfolio a defensive backbone. On the softer side, AstraZeneca and Nestlé have been more mixed, occasionally losing steam. Overall, the ETF leans into developed markets outside North America, with a balanced mix of European and Asian blue chips.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 NL:ASML | ASML Holding NV | 3.02% | $196.86M | EUR 539.67B | 50.70% | 76Outperform |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 GB:SHEL | Shell (UK) | 1.47% | $95.76M | GBP 229.30B | 40.01% | 73Outperform |
 CH:NOVN | Novartis AG | 1.43% | $93.31M | CHF 244.89B | 35.30% | 80Outperform |
 GB:HSBA | HSBC Holdings | 1.39% | $90.38M | GBP 218.81B | 19.37% | 80Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 CH:NESN | Nestlé SA | 1.17% | $76.45M | CHF 217.87B | 9.36% | 71Outperform |
 JP:8306 | Mitsubishi UFJ Financial Group | 1.16% | $75.57M | JPY 38.80T | 48.45% | 76Outperform |
 DE:SAP | SAP SE | 1.05% | $68.45M | EUR 246.65B | -6.46% | 66Neutral |
 DE:SIE | Siemens | 1.03% | $67.27M | EUR 202.50B | 7.55% | 74Outperform |
BBIN Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBIN, the sentiment is Negative. The current price of 77.57 is below the 20-day moving average (MA) of 77.61, below the 50-day MA of 78.81, and above the 200-day MA of 76.92, indicating a neutral trend. The MACD of -0.23 indicates Negative momentum. The RSI at 46.76 is Neutral, neither overbought nor oversold. The STOCH value of 70.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BBIN.
BBIN Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| BBIN | $77.57 | $84.00(8.29% Upside) | $6.55B | 0.07% | 66Neutral |
 DBEF | $54.74 | $66.10(20.75% Upside) | $9.37B | 0.35% | 65Neutral |
 EFAV | $96.25 | $103.39(7.41% Upside) | $5.49B | 0.20% | 61Neutral |
 HFXI | $36.35 | $46.18(27.04% Upside) | $2.45B | 0.20% | 58Neutral |
 IHDG | $51.80 | $63.01(21.65% Upside) | $2.07B | 0.58% | 67Neutral |
 DDWM | $45.74 | $53.41(16.77% Upside) | $1.43B | 0.40% | 64Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BBIN | JPMorgan BetaBuilders International Equity ETF | 77.57 | 9.21 | 13.48% | |
| DBEF | Xtrackers MSCI EAFE Hedged Equity ETF | 54.74 | 7.89 | 16.83% | |
| EFAV | iShares MSCI EAFE Min Vol Factor ETF | 96.25 | 14.62 | 17.91% | |
| HFXI | IQ 50 Percent Hedged FTSE International ETF | 36.35 | 5.33 | 17.17% | |
| IHDG | WisdomTree International Hedged Quality Dividend Growth Fund | 51.80 | 5.55 | 12.00% | |
| DDWM | WisdomTree Dynamic Currency Hedged International Equity Fund | 45.73 | 4.77 | 11.63% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.